A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Prevention, management and treatment strategies
Key points
● PU prevention includes: pressure reduction/ redistribution; friction and shear reduction; skin care; and nutrition
● DFU prevention includes; pressure redistribution; prescribing appropriate footware; nail care; emollient use
● Managing the underlying cause of the ulcer is key to treatment
● PU or DFU prevention: both must be tailored to the individual patient
● Ulcers should be monitored at least once a week to assess progress
Authors:
Karen Ousey, University of Huddersfield, England; Paul Chadwick, College of Podiatry, London, England; Arkadiusz Jawień, Collegium Medicum, University of Nicolaus Copernicus, Bydgoszcz, Poland; Gulnaz Tariq, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; Harikrishna K Ragavan Nair, Kuala Lumpur Hospital, Malaysia; José Luis Lázaro-Martínez, Diabetic Foot Unit, Universidad Complutense de Madrid, Spain; Kylie Sandy-Hodgetts, School of Human Sciences, University of Western Australia, Australia; Paulo Alves, Institute of Health Sciences, Catholic University of Portugal, Portugal; Stephanie Wu, Dr William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, United States; Zena Moore, Royal College of Surgeons in Ireland, Dublin, Republic of Ireland
Review panel: Andrea Pokorná, Masaryk University, Czech Republic; Anna Polak, Jerzy Kukuczka Academy of Physical Education in Katowice, Poland; David Armstrong, Keck School of Medicine of University of Southern California, United States; Hiromi Sanada, University of Tokyo, Japan; Joon Pio Hong, Asan Medical Centre, University of Ulsan, South Korea; Leanne Atkin, University of Huddersfield, England; Nick Santamaria, University of Melbourne and Royal Melbourne Hospital, New South Wales, Australia; Peta Tehan, University of Newcastle, Australia; Ralf Lobmann, Klinikum Stuttgart, Germany.
Review panel:
Andrea Pokorná, Masaryk University, Czech Republic; Anna Polak, Jerzy Kukuczka Academy of Physical Education in Katowice, Poland; David Armstrong, Keck School of Medicine of University of Southern California, United States; Hiromi Sanada, University of Tokyo, Japan; Joon Pio Hong, Asan Medical Centre, University of Ulsan, South Korea; Leanne Atkin, University of Huddersfield, England; Nick Santamaria, University of Melbourne and Royal Melbourne Hospital, New South Wales, Australia; Peta Tehan, University of Newcastle, Australia; Ralf Lobmann, Klinikum Stuttgart, Germany.
Authors: Tomasz Bansiewicz, Ibrahim El-Nogoomi and Terry Swanson
Tomasz Bansiewicz, MD, PhD is Professor of Surgery, Department of General and Endocrinological Surgery and Gastroenterological Oncology at H. Święcicki Clinical Hospital in Poznan, Poland
Ibrahim El-Nogoomi, MS, MD, PhD, FRCS is Chair of Department of General Surgery, Kuwait Hospital Sharjah, United Arab Emirates
Terry Swanson, NPWM, MHSc, FMACNP is Fellow Wounds Australia (Co-chair), Wound Education Research Consultancy, Vice Chair International Wound Infection Institute
As technology transforms all sectors in healthcare, there is a need for innovation in learning and professional development. Use of technology such as virtual reality in medical training allows higher levels of interactivity, and the ability to rehearse clinical procedures and refine relevant skills (Herur-Raman, 2021). The new HARTMANN Virtual Reality Wound Care Simulation Training was launched at the World Union of Wound Healing Societies Congress 2022, pioneering a new approach to wound care education.
Patricia B Hotaling is Clinical Assistant Professor, College of Nursing, University of Nebraska Medical Center, Omaha, US; Joyce M. Black is Florence Neidfelt Professor of Nursing, College of Nursing, University of Nebraska Medical Center, Omaha, US
Nafad Mohammad Elhadidi is Consultant General and Vascular Surgeon, General Surgery Department, Zulekha Hospital Sharjah, Al Zahra Street Al Nasserya, Sharjah, United Arab Emirates;
Ahmed Ramadan Wahdan is General Surgery Specialist, Department of Surgery, Al Hammadi Hospital – Al Olaya, Riyadh, Saudi Arabia; Mohamed Abouzeid
Ahmed Gaballa Ali is General Surgery Consultant, Diabetic Foot and Chronic Wounds care unit, Exir Subspecialities Medical Centre, Jahra, Kuwait
The Arabian Gulf region has seen an increasing rise in diabetic foot ulcers (DFUs) with prevalence ranging from 4.7% to 19% in Saudi Arabia (Hu et al, 2014; Mairghani et al, 2017). Current practices for standard of care include wound debridement, wound offloading and dressings. The authors successfully managed diabetic foot ulcers with oxygen free-radical binding technology as an adjuvant therapy for our patients. HemaGel® (VH Pharma), a hydrophilic gel, contains sterically hindered amines that bind with reactive oxygen species (ROS) and thereby accelerates wound healing by showing an anti-inflammatory effect. The three case reports in this article discuss the use of targeted oxygen free radicals to promote wound healing by oxidant/antioxidant disequilibrium methodology in the authors’ patients. With supporting diabetes controlling medications and HemaGel, wound healing was achieved successfully in these patients.
Authors (clockwise from top left): Naser Alhumaidi, Mariam Alessa, Abdul Aziz Alshahe and Emilio Galea
Naser Alhumaidi is Senior Specialist in General Surgery, Head of Diabetic Foot Unit Department of Surgery, Farwaniya Hospital, Kuwait; Mariam Alessa is Diabetes Specialist Podiatrist, Diabetic Foot Unit Department of Surgery, Farwaniya Hospital, Kuwait; Abdul Aziz Alshaheen is General Practitioner Surgery, Diabetic Foot Unit Department of Surgery, Farwaniya Hospital, Kuwait; Emilio Galea is International Medical Director, Urgo Medical
Chronic wounds are an international and regional concern affecting many patients, demanding substantial resources from healthcare systems. Managing patients with these wounds is costly in terms of time and resources required, not forgetting the detrimental impact on the quality of life of these individuals. Moreover, diabetic foot problems are very common throughout the world, and their recurrence is high. In 2016, the World Health Organization (WHO, 2022)reported that 14.7% of the population of Kuwait are suffering from diabetes, with very high percentages of overweight, obese and inactive individuals. It is inevitable that many of these individuals suffer and/or will suffer in the future from diabetes-related foot ulcers and complications, and the management of these wounds is complex. The authors reviewed the evidence behind a local treatment indicated for chronic wounds and specific in neuropathic diabetic foot ulcers. In view of the high level of evidence regarding this local treatment, a pilot study was conducted in 2021 to analyse the feasibility of a larger-scale observational study. The article highlights the results of the initial pilot and discusses the feasibility of conducting further research to justify implementation of technology lipido-colloid nano oligosaccharide factor(TLC-NOSF) dressings in the local management of patients with diabetic foot ulcers in Kuwait.
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。